Data from the DUO-E trial support the FDA approval of durvalumab/chemotherapy for those with primary advanced or recurrent dMMR endometrial cancer.
Approval Alert | Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
2
AVZO-1418/DB-1418 Earns FDA Fast Track Designation For EGFR-Mutated NSCLC
3
FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs
4
Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research
5
